Chris Coffey retweeted
🔥 🧠 We are at the @AANmember Autoimmune Neurology Meeting -
Come by and Pick Up something fun to promote awareness and recognition of NMDAR Encephalitis (and the ongoing ExTINGUISH clinical trial to learn how to better treat patients!)
Chris Coffey retweeted
An invited editorial explores how the @MichaelJFoxOrg's PPMI programme is enabling the first interventional platform trial ("Path to Prevention" or P2P) to test therapies in individuals with Early-Stage Neuronal Alpha-Synuclein Disease
onlinelibrary.wiley.com/doi/…
Chris Coffey retweeted
An invited editorial describes lessons learned from prior enrollment & current strategies for enrolling participants to the @MichaelJFoxOrg PPMI programme prior to the diagnosis of #Parkinsons or dementia with Lewy Bodies
onlinelibrary.wiley.com/doi/…
Chris Coffey retweeted
SOLD-OUT CROWD IN IOWA CITY‼️
If you aren't watching women's sports, you're missing out!
#MarchMadness x @IowaWBB
Chris Coffey retweeted
Stakeholders involved in Parkinson’s platform trials met for the second annual International PD-Platform Meeting. They launched the Global Alliance for Parkinson’s Platforms (GAPP), bringing together international leaders of Parkinson’s platform trials: buff.ly/RoM8laO
Chris Coffey retweeted
Can 'light therapy' help people w/ Parkinson’s sleep better? The ENLITE-PD randomized study put this idea to the test. Aleksandar Videnovic and colleagues did a great job on this multi-center effort. Spoiler alert: bright white light therapy was not effective.
Key Points:
- Bright white light therapy was safe, well tolerated and had good adherence across groups.
- Twice-daily light therapy showed some improvements in sleep and fatigue, however it did not meet criteria to advance to a phase 3 trial.
- Once weekly bright light was non-inferior to dim red light and may serve as a better control condition for future studies.
My take: I think it is critically important to put non-pharmacological therapies to the test, and I congratulate the authors for conducting this study. Right now, it looks light the ‘juice may not be worth the squeeze’ for the current versions of light therapy for Parkinson’s. Here are 5 points that resonated w/ me about this article: 1- Sleep issues frequently affect people living w/ Parkinson’s and remain a major unmet need. 2- Light therapy is safe and may help improve fatigue and aspects of sleep, however the benefits were modest in this trial. 3- Not all light therapies are the same and more research is needed to determine frequency, timing and type of light that work best. 4- This study highlights the importance of rigorous trials to sort out real benefits from placebo and also from the effects of daily rhythm. 5- Future light therapy studies will need longer durations, diverse populations and objective measures to truly understand if there is a potential we are missing.
movementdisorders.onlinelibr… @FixelInstitute @ParkinsonDotOrg @movedisorder @SfNtweets
Chris Coffey retweeted
If you'll be at #JSM2025 next week, come check out some of our @Iowa_Biostat current students and faculty present their research!
Chris Coffey retweeted
The ExTINGUISH Trial Methods Paper is available, Open Access!
👉There are no approved (or rigorously studied) treatments for NMDAR Encephalitis.
👉 Enrollment is ongoing for newly diagnosed NMDAR Encephalitis patients, via NIH/NINDS & the NeuroNEXT Clinical Trial Network
A Phase-2B Double-Blind Randomized International Prospective Trial of Inebilizumab in NMDAR Encephalitis: The ExTINGUISH Trial
hubs.la/Q03wXfmN0
Chris Coffey retweeted
Just published 👉
A NEWLY updated, comprehensive meta-analysis of the treatment of anti-NMDAR encephalitis: Analysis, equipoise, and the urgent need for evidence over anecdote 🧠🔥
Why is this paper so important ?
1/
Chris Coffey retweeted
Berry Consultants is proud to sponsor and attend the upcoming Society for Clinical Trials (SCT) 46th Annual Meeting in Vancouver, British Columbia, Canada on May 18-21.
Multiple Berry Consultants team members will be presenting in a range of innovative clinical trial sessions:
• May 20, 1pm PDT: “Harnessing the Potential of Platform Trials in Chronic Diseases”, Barbara Wendelberger, Ph.D.
• May 20, 4pm PDT: “Stopping Progress: Finding Effective Treatments Using Disease Progression Modeling”, Thomas Jensen, M.S.
• May 21, 11am PDT: “Planning for Heterogeneous Treatment Effects: Enrichment for Treatment-Sensitive Patient Populations”, Giorgio Paulon, Ph.D.
For more about our team’s upcoming sessions, here is a short preview video: youtube.com/watch?v=tDTf9ZCZ…
Hope to see you there! #SCT2025
Chris Coffey retweeted
Being involved in the @extinguishtrial for NMDAR Encephalitis is the honor - and challenge - of a lifetime.
And our community is making it a reality ❤️
Fantastic updates:
📣 As of 2025 ALL 37 US and 2 EU ExTINGUISH Trial sites are enrolling patients with NMDAR Encephalitis 1/
Chris Coffey retweeted
📣The Iowa Chapter of the ASA 2025 Annual Meeting is coming up! Check out the meeting website, register, and come on April 11 at Grinnell College's campus: stats-tgeorge.quarto.pub/iow…
Chris Coffey retweeted
Such a wonderful opportunity to chat with the Encephalitis Society to discuss why Clinical Trials are such a valuable opportunity for patients affected by neurologic disease.
The ExTINGUISH Trial for acute NMDAR Encephalitis in enrolling now 🧠 🔥
Podcast Link in comments 👇
Chris Coffey retweeted
The swift developments we witnessed during COVID-19 demonstrated the immense potential of adaptive clinical trials — highlighting the urgent need to design trials that facilitate faster learning and smarter decision-making.
Though tools like ChatGPT can provide algorithmic instructions, they can't yet replace human expertise in posing the right questions to drive adaptive designs. Having the correct instructions is one thing but knowing the best methods to implement them effectively is the real issue.
If you're contemplating whether an adaptive design might suit your research, listen to our full podcast episode 2, "When Should You Use Adaptive Design Clinical Trials": berryconsultants.com/podcast
#BerryConsultants #IntheInterimPodcast
Chris Coffey retweeted
Swimming & Diving: Both @LFC_swimdive teams placed 3rd at the 2025 MWC Championship Meet (Final). At the four-day meet Lake Forest swimmers won six events, set seven school and two meet records, and made 22 updates to the program's list of the top-five performers in each event. #GoForesters
Chris Coffey retweeted
UPSET CITY.
#Hawkeyes
Chris Coffey retweeted
Michael J Fox honored by President Biden
Well deserved, a great actor and God bless him, always
Chris Coffey retweeted
Great news for 2025 - more sites have been activated, to allow more NMDAR encephalitis patients (ages 12 and up) the opportunity to enroll in the ExTINGUISH Trial, even closer to home.
Thankful to everyone who has worked to make this happen 🧠 🔥 🤝
Chris Coffey retweeted
National Institute of Neurological Disorders and Stroke Clinical Trials Methodology Course: Summary and Accomplishments 2014–2023 bit.ly/4iCinaN
#NeurologyEd #NeuroTwitter
































